DarioHealth Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Erez Raphael
- Full Time Employees
- 196
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 18 West 18th Street New York City NY United States of America 10011
- IPO Date
- Mar 14, 2016
- CIK
- 0001533998
- Website
- mydario.com
- Similar Companies
- Business
- DarioHealth Corp. (NASDAQ: DRIO) operates as a global digital therapeutics company that delivers personalized, evidence-based interventions through its user-centric platform, integrating software, connected devices, AI-driven data analytics, and one-on-one coaching to manage chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain such as posture, injury, and pain issues, and behavioral health conditions like anxiety, depression, and stress; core offerings encompass the Dario mobile app with real-time monitoring and hypo-alerts, DarioEngage population health management platform, Dario Loop AI journey engine, Dario Tools smartphone-integrated devices, digital coaching via chat with educational content, and expanded GLP-1 solutions with prescribing capabilities, targeting health plans, self-insured employers, providers, pharmaceutical companies, and direct-to-consumer markets primarily through B2B2C channels in the United States, Canada, the European Union, Australia, and New Zealand. Founded in 2011 as LabStyle Innovations Corp. in Caesarea, Israel, with principal executive offices in New York and ongoing R&D in Israel, the company focuses on disrupting traditional episodic healthcare with continuous, customized care to drive sustainable behavior change and clinical outcomes like HbA1c reductions and risk diminutions. Recent developments include the strategic acquisition of Twill in early 2024 to broaden multi-condition offerings and achieve immediate scale with top national health plans and Fortune 100 employers, a $25.6 million private placement in 2025 to fund growth toward operational cash flow positivity by year-end, new partnerships such as with BCBS launched in January 2025 and MediOrbis for GLP-1 expansions, signing of four new employer contracts and 79 new accounts exceeding 2025 targets as of December 2025, and contracts covering over 2.8 million eligible lives with demonstrated revenue growth including 111% year-over-year in Q3 2024.
Dario More Than Doubles Addressable Market in Solera Health's Network via Expanded Hypertension Program, With Dario Now Reaching Greater Than 500,000 Eligible Lives
DarioHealth Corp. (DRIO) Q1 2026 Earnings Call Transcript
DarioHealth Q1 Earnings Call Highlights
DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates
DarioHealth Reports First Quarter 2026 Financial and Operating Results
DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
Contrasting DarioHealth (NASDAQ:DRIO) & Thermo Fisher Scientific (NYSE:TMO)
DarioHealth Q4 Earnings Call Highlights
DarioHealth Corp. (DRIO) Q4 2025 Earnings Call Transcript
DarioHealth Corp. (DRIO) Reports Q4 Loss, Beats Revenue Estimates
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
Contrasting DarioHealth (NASDAQ:DRIO) and CardioGenics (OTCMKTS:CGNH)
Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio